Technical Summary

• The present invention relates to an antibiotic composition against antibiotic-resistant strains including phellinstatin or hispidin, which is isolated from Phellinus linteus 08090-29 strain, as an effective component.
• It has been confirmed through experiments that the antibiotic composition inhibits activities of enoyl-ACP reductase, which emerged as a new antibiotic target, and has antibiotic activities against antibiotic-resistant strains.
• An antibiotic activity test has been completed.
  

Technical Superiority

Potent antibiotic resistance against pathogenic microorganisms/ antibiotic-resistant strains

• The antibiotic composition functions to inhibit the activities of Enzymes Fab I and Fab K.
• It has been confirmed that the antibiotic composition shows antibiotic activities against the resistant strains.
• The antibiotic composition has effects of preventing and treating infectious diseases caused by super bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).

Applicability to various forms

• The antibiotic composition may be formulated into forms such as oral preparations, external preparations, suppositories and sterile injectable solutions.
• The antibiotic composition may be administered via various routes of administration such as intravenously, subcutaneously and intraperitoneally.
  

Applications

Pharmaceutical compositions

• Oral preparations: solid and liquid preparations
• Parenteral preparations: injectable preparations, aqueous solutions, non-aqueous solvents, emulsions and suppositories

Quasi-drug compositions

• The compositions may be prepared into sanitizers, soaps, detergents, humidifier fillers, filter fillers and masks.

Please see flyer for major technical data.